Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Total Non-Current Liabilities (2023 - 2025)

Krystal Biotech's Total Non-Current Liabilities history spans 3 years, with the latest figure at $110.5 million for Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities rose 2.31% year-over-year to $110.5 million; the TTM value through Dec 2025 reached $110.5 million, up 2.31%, while the annual FY2025 figure was $110.5 million, 2.31% up from the prior year.
  • Total Non-Current Liabilities for Q4 2025 was $110.5 million at Krystal Biotech, up from $99.1 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $110.5 million in Q4 2025 and bottomed at $39.7 million in Q4 2023.
  • The 3-year median for Total Non-Current Liabilities is $95.3 million (2024), against an average of $89.2 million.
  • The largest annual shift saw Total Non-Current Liabilities surged 172.04% in 2024 before it increased 2.31% in 2025.
  • A 3-year view of Total Non-Current Liabilities shows it stood at $39.7 million in 2023, then soared by 172.04% to $108.0 million in 2024, then grew by 2.31% to $110.5 million in 2025.
  • Per Business Quant, the three most recent readings for KRYS's Total Non-Current Liabilities are $110.5 million (Q4 2025), $99.1 million (Q3 2025), and $94.9 million (Q2 2025).